Dolutegravir is a first-line treatment for newly diagnosed HIV patients
A new study by UBC researchers is set to change international treatment recommendations for people who are newly diagnosed with HIV — an update that could affect nearly two million people per year worldwide. The study found that dolutegravir is the optimal medication for first-line treatment for people newly diagnosed with HIV, a choice that has not
Dolutegravir is a first-line treatment for newly diagnosed HIV patients Read More »